

Suzette Delaloge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8189667/publications.pdf>

Version: 2024-02-01

110
papers

16,283
citations

36303

51
h-index

27406

106
g-index

116
all docs

116
docs citations

116
times ranked

20737
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. <i>Nature Medicine</i> , 2007, 13, 1050-1059. | 30.7 | 2,657 |
| 2 | Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 523-533. | 27.0 | 2,256 |
| 3 | 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 717-729. | 27.0 | 1,427 |
| 4 | Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309. | 30.7 | 823 |
| 5 | The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. <i>Immunological Reviews</i> , 2007, 220, 47-59. | 6.0 | 491 |
| 6 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700. | 10.7 | 451 |
| 7 | Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 367-377. | 10.7 | 444 |
| 8 | Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period. <i>Journal of Clinical Oncology</i> , 2004, 22, 3302-3308. | 1.6 | 389 |
| 9 | Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978. | 12.6 | 367 |
| 10 | 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347. | 27.0 | 363 |
| 11 | Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. <i>Annals of Oncology</i> , 2021, 32, 1216-1235. | 1.2 | 354 |
| 12 | Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2008, 14, 7004-7010. | 7.0 | 350 |
| 13 | Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array. <i>Clinical Cancer Research</i> , 2009, 15, 441-451. | 7.0 | 300 |
| 14 | Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8331-8339. | 1.6 | 266 |
| 15 | First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 921-929. | 1.6 | 244 |
| 16 | Dual-energy contrast-enhanced digital mammography: initial clinical results. <i>European Radiology</i> , 2011, 21, 565-574. | 4.5 | 233 |
| 17 | Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. <i>European Journal of Cancer</i> , 2018, 96, 17-24. | 2.8 | 211 |
| 18 | Long-Term Cardiovascular Mortality After Radiotherapy for Breast Cancer. <i>Journal of the American College of Cardiology</i> , 2011, 57, 445-452. | 2.8 | 191 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Laser thermal therapy: Real-time MRI-guided and computer-controlled procedures for metastatic brain tumors. <i>Lasers in Surgery and Medicine</i> , 2011, 43, 943-950. | 2.1 | 184 |
| 20 | 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488. | 10.7 | 179 |
| 21 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 687-705. | 27.6 | 178 |
| 22 | An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. <i>American Journal of Surgery</i> , 2003, 185, 158-164. | 1.8 | 175 |
| 23 | Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 60-72. | 10.7 | 161 |
| 24 | Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150. | 10.7 | 147 |
| 25 | Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 292-300. | 1.6 | 140 |
| 26 | First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220. | 2.2 | 135 |
| 27 | <i>CDH1</i> germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. <i>Journal of Medical Genetics</i> , 2013, 50, 486-489. | 3.2 | 131 |
| 28 | Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. <i>British Journal of Cancer</i> , 2019, 121, 991-1000. | 6.4 | 113 |
| 29 | Added value of Virtual Touch IQ shear wave elastography in the ultrasound assessment of breast lesions. <i>European Journal of Radiology</i> , 2014, 83, 773-777. | 2.6 | 103 |
| 30 | Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. <i>European Journal of Cancer</i> , 2020, 129, 60-70. | 2.8 | 103 |
| 31 | A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 429-437. | 2.5 | 99 |
| 32 | Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. <i>Autophagy</i> , 2015, 11, 1878-1890. | 9.1 | 91 |
| 33 | The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. <i>Autophagy</i> , 2016, 12, 864-875. | 9.1 | 90 |
| 34 | Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy. <i>Cancer Research</i> , 2013, 73, 2247-2258. | 0.9 | 86 |
| 35 | New potential and applications of contrast-enhanced ultrasound of the breast: Own investigations and review of the literature. <i>European Journal of Radiology</i> , 2009, 69, 14-23. | 2.6 | 82 |
| 36 | Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. <i>Journal of Clinical Oncology</i> , 2020, 38, 2762-2772. | 1.6 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Triple-negative breast cancer: are we making headway at least?. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 195-210. | 3.2 | 75 |
| 38 | Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30. | 2.8 | 75 |
| 39 | Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. <i>Cell Death and Differentiation</i> , 2021, 28, 2778-2796. | 11.2 | 72 |
| 40 | A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. <i>Investigational New Drugs</i> , 2012, 30, 1193-1202. | 2.6 | 71 |
| 41 | Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. <i>Nature Communications</i> , 2020, 11, 3819. | 12.8 | 71 |
| 42 | Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). <i>Journal of Clinical Oncology</i> , 2020, 38, 734-743. | 1.6 | 69 |
| 43 | Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1236-1238. | 1.6 | 65 |
| 44 | Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. <i>Cancer</i> , 2004, 101, 918-925. | 4.1 | 62 |
| 45 | The role of Oncoplastic Breast Surgery in the management of breast cancer treated with primary chemotherapy. <i>Breast</i> , 2013, 22, 1189-1193. | 2.2 | 60 |
| 46 | CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. <i>Oncologist</i> , 2009, 14, 1182-1188. | 3.7 | 59 |
| 47 | Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. <i>Radiotherapy and Oncology</i> , 2010, 96, 199-203. | 0.6 | 59 |
| 48 | Exploring frontiers: Use of complementary and alternative medicine among patients with early-stage breast cancer. <i>Breast</i> , 2014, 23, 279-285. | 2.2 | 59 |
| 49 | Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 361-370. | 10.7 | 59 |
| 50 | Ki67â€™no evidence for its use in node-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 296-301. | 27.6 | 58 |
| 51 | Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. <i>Cancer</i> , 2006, 107, 1459-1466. | 4.1 | 55 |
| 52 | Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. <i>Lancet Oncology</i> , The, 2009, 10, 381-390. | 10.7 | 55 |
| 53 | SARS-CoV-2 vaccines for cancer patients: a call to action. <i>European Journal of Cancer</i> , 2021, 148, 316-327. | 2.8 | 55 |
| 54 | Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. <i>Anticancer Research</i> , 2007, 27, 547-55. | 1.1 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Chk1 as a new therapeutic target in triple-negative breast cancer. <i>Breast</i> , 2014, 23, 250-258. | 2.2 | 50 |
| 56 | Therapeutic vaccines for breast cancer: Has the time finally come?. <i>European Journal of Cancer</i> , 2022, 160, 150-174. | 2.8 | 49 |
| 57 | MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, 506-506. | 1.6 | 44 |
| 58 | Outcome in breast molecular subtypes according to nodal status and surgical procedures. <i>American Journal of Surgery</i> , 2013, 205, 662-667. | 1.8 | 43 |
| 59 | DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 341-345. | 1.3 | 39 |
| 60 | Targeting PI3K/AKT pathway in triple-negative breast cancer. <i>Lancet Oncology, The</i> , 2017, 18, 1293-1294. | 10.7 | 39 |
| 61 | Added Value of Contrast-Enhanced Spectral Mammography in Postscreening Assessment. <i>Breast Journal</i> , 2016, 22, 520-528. | 1.0 | 38 |
| 62 | Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231. | 30.7 | 38 |
| 63 | Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the <sc>E3Nâ€¦EPIC</sc> cohort. <i>International Journal of Cancer</i> , 2016, 138, 2415-2427. | 5.1 | 37 |
| 64 | Multicenter evaluation of breast cancer patientsâ€™ satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic. <i>British Journal of Cancer</i> , 2021, 125, 1486-1493. | 6.4 | 37 |
| 65 | The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. <i>European Journal of Cancer</i> , 2016, 66, 131-137. | 2.8 | 33 |
| 66 | Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. <i>Npj Breast Cancer</i> , 2021, 7, 41. | 5.2 | 33 |
| 67 | Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the â€œMy Personal Breast Screeningâ€•(MyPeBS) randomised clinical trial. <i>BMC Cancer</i> , 2022, 22, 507. | 2.6 | 32 |
| 68 | The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 703-716. | 4.2 | 28 |
| 69 | A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423. | 9.4 | 28 |
| 70 | Value of whole breast magnetic resonance elastography added to MRI for lesion characterization. <i>NMR in Biomedicine</i> , 2018, 31, e3795. | 2.8 | 25 |
| 71 | Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancerâ€™ an European consensus statement and expert recommendations. <i>European Journal of Cancer</i> , 2019, 106, 54-60. | 2.8 | 25 |
| 72 | Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021, 153, 123-132. | 2.8 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Gemcitabine in Patients With Solid Tumors and Renal Impairment. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 289-293. | 1.3 | 23 |
| 74 | Diagnostic Performance of MR-guided Vacuum-Assisted Breast Biopsy: 8 Years of Experience. <i>Breast Journal</i> , 2016, 22, 83-89. | 1.0 | 23 |
| 75 | Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 1111-1123. | 1.6 | 23 |
| 76 | Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. <i>BMJ Open</i> , 2022, 12, e055821. | 1.9 | 23 |
| 77 | Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204. | 1.6 | 23 |
| 78 | Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. <i>European Journal of Cancer</i> , 2017, 75, 323-332. | 2.8 | 22 |
| 79 | Patient-assisted compression helps for image quality reduction dose and improves patient experience in mammography. <i>European Journal of Cancer</i> , 2018, 103, 137-142. | 2.8 | 21 |
| 80 | Effects of local laser treatment on vulvovaginal atrophy among women with breast cancer: a prospective study with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 501-509. | 2.5 | 18 |
| 81 | Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77. | 2.8 | 18 |
| 82 | Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2148-2162. | 1.6 | 18 |
| 83 | Patient satisfaction with a rapid diagnosis of suspicious breast lesions: Association with distress and anxiety. <i>Breast Journal</i> , 2018, 24, 154-160. | 1.0 | 17 |
| 84 | Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG) Tj ETQq0 0 0.2 BT / Overlock 10 T | | |
| 85 | Impact of body mass index on overall survival in patients with metastatic breast cancer. <i>Breast</i> , 2021, 55, 16-24. | 2.2 | 17 |
| 86 | Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2000-2000. | 1.6 | 17 |
| 87 | Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS. <i>Analytical Chemistry</i> , 2022, 94, 6297-6303. | 6.5 | 13 |
| 88 | Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. <i>European Journal of Cancer</i> , 2022, 166, 300-308. | 2.8 | 11 |
| 89 | Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3699-3708. | 1.6 | 11 |
| 90 | UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup. <i>European Journal of Cancer</i> , 2019, 122, 91-100. | 2.8 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. <i>Oncolmmunology</i> , 2021, 10, 1859064. | 4.6 | 6 |
| 92 | Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database. <i>Breast</i> , 2021, 60, 138-146. | 2.2 | 5 |
| 93 | A response letter to comments on “Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016”, <i>European Journal of Cancer</i> , 2020, 140, 165-166. | 2.8 | 4 |
| 94 | Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing. <i>Cancer Research</i> , 2020, 80, 2190-2203. | 0.9 | 4 |
| 95 | Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study. <i>Breast Cancer Research</i> , 2021, 23, 9. | 5.0 | 4 |
| 96 | MyPeBS International randomized study comparing personalised, risk-stratified to standard breast cancer screening in women aged 40-70: Focus on recruitment strategy in France. <i>La Presse Médicale Open</i> , 2022, 3, 100022. | 0.4 | 4 |
| 97 | Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful?. <i>European Journal of Cancer</i> , 2017, 85, 23-30. | 2.8 | 3 |
| 98 | Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual & volumetric analysis. <i>British Journal of Radiology</i> , 2018, 91, 20170163. | 2.2 | 3 |
| 99 | Routinely collected data may usefully supplement randomised controlled data on treatment effects for mortality. <i>BMJ</i> , The, 2016, 355, i6745. | 6.0 | 2 |
| 100 | Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016. <i>European Journal of Cancer</i> , 2020, 137, 240-249. | 2.8 | 2 |
| 101 | BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial. <i>Quality of Life Research</i> , 2021, , 1. | 3.1 | 2 |
| 102 | Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1087-1087. | 1.6 | 2 |
| 103 | Addressing the issue of bias in observational studies: Using instrumental variables and a quasi-randomization trial in an ESME research project. <i>PLoS ONE</i> , 2021, 16, e0255017. | 2.5 | 1 |
| 104 | Prognostic and predictive value of tumor infiltrating lymphocytes (TIL) in two phase III randomized adjuvant breast cancer (BC) trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11087-11087. | 1.6 | 1 |
| 105 | Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries. <i>Breast Journal</i> , 2016, 22, 96-100. | 1.0 | 0 |
| 106 | Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects?. <i>European Journal of Cancer</i> , 2017, 77, 153-154. | 2.8 | 0 |
| 107 | All simulation models of breast cancer are wrong but some are useful. <i>The Lancet Global Health</i> , 2018, 6, e818-e819. | 6.3 | 0 |
| 108 | Nonmetastatic inflammatory breast cancer: Evolution of invasive disease-free (IDFS) and overall survival (OS) over a 21-year period.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1082-1082. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Clock genes expression in breast cancers (BC) from patients (pts) treated with neoadjuvant chemotherapy (NAC) in a randomized multicenter phase II trial.. Journal of Clinical Oncology, 2014, 32, e11528-e11528. | 1.6 | 0 |
| 110 | Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.. Journal of Clinical Oncology, 2020, 38, TPS1107-TPS1107. | 1.6 | 0 |